Nanomedicine: Enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation

Current Pharmaceutical Design

Volumn 16, Issue 21, 2010, Pages 2308-2320

  Gan, Chee Wee ^a   Chien, Shu ^b   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticancer drugs; Biodegradable polymers; Cancer nanotechnology; Chemotherapeutic engineering; Nanomedicine

Indexed keywords

COPOLYMER; DOCETAXEL; NANOPARTICLE; PACLITAXEL; POLY(LACTIC ACID) DEXTRO ALPHA TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYVINYL ALCOHOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIODEGRADABILITY; BLOOD BRAIN BARRIER; CANCER CELL; CANCER CHEMOTHERAPY; CELL ADHESION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG UPTAKE; EMULSION; ENCAPSULATION; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; INTERNALIZATION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM; SYNTHESIS; ULTRASOUND; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG SYNERGISM; HUMANS; NANOMEDICINE; NANOPARTICLES; TAXOIDS; TREATMENT OUTCOME;

EID: 77955627105     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791920487     Document Type: Article

References (53)

1. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006; 58(14): 1456-59.
2. Feng SS. Nanomedicine: Nanoparticles of Biodegradable Polymers for Cancer Diagnosis and Treatment. COSMOS - An Interdisciplinary. J Sci Singapore Natl Acad Sci 2008; 4(2): 185-201.
3. Feng SS, Zhao LY, Zhang ZP, et al. Chemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo. Chem Eng Sci 2007; 62(23): 6641-48.
4. Feng SS, Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 2003; 58(18): 4087-114.
5. van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)- modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 2007; 24(8): 1405-14.
6. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001; 47(1): 113-31.
7. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable longcirculating polymeric nanospheres. Science 1994; 263(5135): 1600-3.
8. Langer R. Drug delivery: drugs on target. Science 2001; 293(5527): 58-9.
9. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5(3): 161-71.
10. Vakil R, Kwon GS. Poly(ethylene glycol)-b-poly(ε-caprolactone) and PEG-phospholipid form stable mixed micelles in aqueous media. Langmuir 2006; 22(23): 9723-9.
11. Feng SS. New-concept chemotherapy by nanoparticles of biodegradable polymers -where are we now? Nanomedicine 2006; 1(3): 297-309.
12. Bazile D, Prud'homme G, Bassoullet MT. Stealth MePEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995; 84(4): 493-8.
13. Allen MT. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv Drug Deliv Rev 1994; 13(3): 285-309.
14. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticleaptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 2004; 64(21): 7668-72.
15. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54(5): 631-51.
16. Duncan, R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2(5): 347-60.
17. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncology 2004; 9 (Suppl 2): 3-8.
18. ten Tije AJ, Loos WJ, Verweij J, et al. Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches. Clin Pharmacol Ther 2003; 74(5): 509-10.
19. Engels FK, Mathot RAA, Verweij J. Alternative drug formulations of Docetaxel: a review. Anti-Cancer Drugs 2007; 18(2): 95-103.
20. Yu DH, Lu Q, Xie J, et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010; 31(8): 2278-92.
21. Ma GL, Yang J, Zhang LH, et al. Effective antitumor activity of paclitaxel-loaded poly (epsilon-caprolactone)/pluronic F68 nanoparticles after intratumoral delivery into the murine breast cancer model. Anticancer Drug 2010; 21(3): 261-9.
22. He XZ, Ma JY, Mercado AE, et al. Cytotoxicity of Paclitaxel in biodegradable self-assembled core-shell poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles. Pharm Res 2008; 25(7): 1552-62.
23. Zhang ZP, Lee SH, Gan CW, et al. Pharmacokinetics, biodistribution and xenograft tumor model of PLA-TPGS nanoparticles prepared by dialysis method for controlled and sustained small molecule chemotherapy. Pharm Res 2008; 25(8): 1925-35.
24. Sheu MT, Chen SY, Chen LC, et al. Influence of micelle solubilization by tocopheryl polyethylene glycol succinate (TPGS) on solubility enhancement and percutaneous penetration of estradiol. J Control Release 2003; 88(3): 355-68.
25. Win KY, Feng SS. In vitro and in vivo studies on vitamin E TPGSemulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 2006; 27(10): 2285-91.
26. Woodcock DM, Linsenmeyer ME, Chojnowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992; 66(1): 62-8.
27. Collnot EM, Baldes C, Wempe MF, et al. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 2007; 4(3): 465-74.
28. Varma MVS, Ashokraj Y, Dey CS, et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48(4): 347-59.
29. Varma MVS, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005; 25(4-5): 445-53.
30. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 2006; 8: 343-75.
31. Feng SS. Nanoparticles of biodegradable polymers for cancer diagnosis and treatment (the first-ever SnapShot of the Journal). Biomaterials 2008; 29(30): 4146-7.
32. Birringer M, EyTina JH, Salvatore BA, et al. Vitamin E analogues as inducers of apoptosis: structure-function relation. Br J Cancer 2003; 88(12): 1948-55.
33. Neuzil J. Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity. Br J Cancer 2003; 89(10): 1822-6.
34. Momot KI, Kuchel PW, Chapman BE, et al. NMR study of the association of propofol with nonionic surfactants. Langmuir 2003; 19(6): 2088-95.
35. Couvreur P, Puisieux F. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Deliv Rev 1993; 10(2-3): 141-62.
36. Yuan F, Leuning M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in human tumor xenograft. Cancer Res 1994; 54(13): 3352-6.
37. Savic R, Luo L, Eisenberg A, et al. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 2003; 300(5619): 615-8.
38. Müller RH. Colloidal carriers for controlled drug delivery and targeting: modification, characterization and in vivo distribution; In: Müller RH, Ed. Florida: CRC Press 1991; pp. 57-97.
39. Mohamed F, van der Walle CF. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 2008; 97(1): 71-87.
40. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 2008; 364(2): 298-327.
41. Bouissou C, Potter U, Altroff H, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. J Control Release 2004; 95(3): 557-66.
42. Hu K, Li J, Shen Y, et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vivo and in vivo evaluations. J Control Release 2009; 134(1): 55-61.
43. Hill BT, Whelan RDH, Shellard SA, et al. Differential cytotoxic effects of Docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994; 12(3): 169-82.
44. Bissery MC. Preclinical pharmacology of docetaxel. Eur J Cancer 1995; (Supp 4): S1-6.
45. Dong Y, Feng SS. In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for smallmolecule drug chemotherapy. Biomaterials 2007; 28(28): 4154-60.
46. Senthilkumar M, Mishra P, Jain NK. Long circulating PEGylated poly(D,L-lactide-co-glycolide) nanoparticulate delivery of Docetaxel to solid tumors. J Drug Target 2008; 16(5): 424-35.
47. Hume DA. The mononuclear phagocyte system. Curr Opin Immunol 2006; 18(1): 49-53.
48. Riou JF, Naudin A, Lavelle E. Effects of Taxotere on murine and human tumor cell line. Biochem Biophys Res Commun 1992; 187(1): 164-70.
49. ®) in human tumour cell lines. Br J Cancer 1993; 68(6): 1104-9.
50. Hurria A, Fleming MT, Baker SD, et al. Pharmacokinetics and toxicity of weekly Docetaxel in older patients. Clin Cancer Res 2006; 12(20): 6100-5.
51. Agarwal A, Lariya N, Saraogi G, Dubey N, Agrawal H, Agrawal GP. Nanoparticles as novel carrier for brain delivery: a review. Curr Pharm Des 2009; 15(8): 917-25.
52. Debbage P. Targeted drugs and nanomedicine: present and future. Curr Pharm Des 2009; 15(2): 153-172.
53. Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Curr Pharm Des 2004; 10(12): 1355-63.